Canada's Nuvo Research will buy Zars Pharma, a U.S.-based specialty pharmaceutical company, for about $13 million, according to a Reuters report.

Zars’ key products include Pliaglis and Synera and focuses on the development pain relieving medications.

"While our initial focus will be on extracting maximum value from the commercialization of Pliaglis and Synera, Zars also brings intriguing pipeline programs," Nuvo chairman Dan Chicoine said in a statement.